Reviva Pharmaceuticals Holdings Inc. Warrants (25/12/2025) RVPHW 深 滬
已收盤 12-12 16:00:00 美东时间
0.003
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.003
- 總市值 2.77万
- 52周最高 0.3678
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.003
- 委 比 0.00%
- 總股本 923.17万
- 歷史最高 3.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.003
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Reviva Updates Brilaroxazine Strategy and Funding Outlook
Reviva Pharmaceuticals Holdings ( ($RVPH) ) just unveiled an announcement. On A...
04-15 20:28
Reviva Pharmaceuticals Holdings Says Aims To Extend Brilaroxazine Patent Life And Exclusivity Potentially Through 2046; To Initiate Trial Activities In Q2 2026, Begin Enrollment In Q3 2026, For RECOVER-2; Preparing To Seek FDA Alignment On New Form Of Brilaroxazine For NDA
Regulation FD Disclosure.On April 15, 2026, Reviva Pharmaceuticals Holdings, Inc. ("Reviva" or the "Company") issued a letter to shareholders announcing certain business updates, including in connection with the
04-15 20:16
Maxim Group Downgrades Reviva Pharmaceuticals to Hold
Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.
04-08 21:20
BRIEF-Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights
BRIEF-Reviva Reports Full Year 2025 Financial Results And Recent Business Highlights March 30 (Reuters) - Reviva Pharmaceuticals Holdings Inc RVPH.O : REVIVA REPORTS FULL YEAR 2025 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS REVIVA PHARMACEUTICALS FY NET INCOME USD -19.9 MILLION REVIVA PHARMACE
03-30 21:57
Reviva Pharmaceuticals Q4 EPS $(0.57) Misses $(0.10) Estimate
Reviva Pharmaceuticals (NASDAQ:RVPH) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.10) by 455.88 percent. This is a 81.1 percent increase over losses of $(3.00) per
03-30 19:57
Reviva FY25 net loss narrows 33.61% to $19.9 million
Reviva FY25 net loss narrows 33.61% to $19.9 million Reviva posted a full-year net loss of $19.9 million, narrowing from $29.9 million. Operating loss tightened to $20.2 million as research and development expense fell to $11.7 million. Cash and cash equivalents ended the year at $14.4 million. FDA
03-30 18:05
Reviva Pharmaceuticals Holdings Inc <RVPH.OQ> expected to post a loss of $1.17 a share - Earnings Preview
Reviva Pharmaceuticals Holdings Inc expected to post a loss of $1.17 a share - Earnings Preview Reviva Pharmaceuticals Holdings Inc RVPH.OQ RVPH.O is expected to show no change in quarterly revenue when it reports results on March 30 (estimated) for the period ending December 31 2025 LSEG's mean
03-27 20:27
What's Behind The Drop In Reviva Pharmaceuticals Stock?
Reviva Pharmaceuticals shares are tumbling Thursday after pricing a $10 million public offering of over 6 million shares at $1.50 per share.
03-20 00:49
BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed
BUZZ-U.S. STOCKS ON THE MOVE-Rivian, Biohaven, CervoMed Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 19 (Reuters) - Wall Street's main indexes were set to open lower on
03-19 21:15
BUZZ-Reviva Pharma plunges on highly dilutive stock-and-warrants offering
BUZZ-Reviva Pharma plunges on highly dilutive stock-and-warrants offering ** Reviva Pharmaceuticals RVPH.O shares plunging 45% to record low $1.03 premarket after follow-on offering priced ** RVPH late Weds sold ~6.7 mln shares along with two series of accompanying warrants at $1.50 for $10 mln gros
03-19 19:44
